Zengxin Gao | Medicine and Health Sciences | Innovative Research Award

Published on by Forensic Scientist

Dr. Zengxin Gao | Medicine and Health Sciences | Innovative Research Award

Department of Orthopedics, Zhongda Hospital, Southeast University School of Medicine | China

Dr. Zengxin Gao is a highly accomplished Chief Physician at Southeast University, Affiliated Zhongda Hospital, recognized for his expertise in orthopedics and minimally invasive spinal interventions. He completed his PhD in Orthopedics at Peking Union Medical College in 2008, following a Master’s degree in Orthopedics (2005) and a Bachelor’s degree in Clinical Medicine from Nanjing Medical University (1990). Dr. Zengxin Gao’s clinical career spans over 30 years, beginning as a physician at Nantong University Affiliated Dongtai Hospital, advancing to attending and associate chief physician, and currently serving as Chief Physician at Southeast University Affiliated Zhongda Hospital since 2015. His research focuses on spinal surgery, intervertebral disc regeneration, and innovative minimally invasive techniques for chronic low back and leg pain, particularly in elderly patients. He has led notable projects, including the Jiangsu Provincial Health Commission’s New Technology Introduction Project on percutaneous single-axis hole microscopy (2021–2023). Dr. Zengxin Gao has made significant scholarly contributions, including sole corresponding authorship in Wenbin Xuan, Yucheng Gao, Zengxin Gao. Intraspinal Bone Fragments Resorption in Thoracolumbar Burst Fracture. JAMA Neurol. 2023;80(11):1248–1249 [Cited 12]; co-first authorship in Linhui Ye, Zengxin Gao, Saeed Rohani. Intervertebral disk regeneration in a rat model by allopurinol-loaded Chitosan/alginate hydrogel. Biomol Biomed. 2023;23(4):661–670 [Cited 5]; and co-corresponding authorship in Shuhua Fang et al. Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression. BMC Musculoskelet Disord. 2024;25:5 [Cited 3]. He has been awarded the Provincial and Ministerial First Prize for the Medical New Technology Introduction Award (2022) for pioneering percutaneous transforaminal endoscopic intervertebral fusion. Dr. Zengxin Gao’s combination of clinical expertise, innovative research, and leadership in orthopedics underscores his outstanding contributions and makes him an ideal candidate for the Innovative Research Award.

Profile: Scopus

Featured Publications

• Xuan, W., Gao, Y., & Gao, Z. (2023). Intraspinal bone fragments resorption in thoracolumbar burst fracture. JAMA Neurology, 80(11), 1248–1249.
https://doi.org/10.1001/jamaneurol.2023.2901

• Ye, L., Gao, Z., & Rohani, S. (2023). Intervertebral disk regeneration in a rat model by allopurinol-loaded chitosan/alginate hydrogel. Biomolecules and Biomedicine, 23(4), 661–670.
https://doi.org/10.17305/bjbms.2023.8535

• Fang, S., Cao, D., Wu, Z., Chen, J., Huang, Y., Shen, Y., & Gao, Z. (2024). Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression. BMC Musculoskeletal Disorders, 25(1), 5.
https://doi.org/10.1186/s12891-023-07172-0

• Gao, Z., Lin, Y., Wu, Z., Zhang, P., Cheng, Q., Ye, L., Wu, F., Chen, Y., Fu, M., Cheng, C., & Gao, Y. (2020). LncRNA SNHG6 can regulate the proliferation and apoptosis of rat degenerate nucleus pulposus cells via regulating the expression of miR-101-3p. European Review for Medical and Pharmacological Sciences, 24(16), 8251–8262.
https://doi.org/10.26355/eurrev_202008_22592

• Gao, Z., Lin, Y., Zhang, P., Cheng, Q., Ye, L., Wu, F., Chen, Y., Fu, M., Cheng, C., & Gao, Y. (2019). Sinomenine ameliorates intervertebral disc degeneration via inhibition of apoptosis and autophagy in vitro and in vivo. American Journal of Translational Research, 11(9), 5956–5966.
https://www.ajtr.org/files/ajtr0094769.pdf

Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Mr. Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Chaoyang Hospital | China

Mr. Zhechun Wu is a resident physician in the Department of Urology at Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, who has established himself as an emerging clinician–scientist combining medical training with impactful research. He earned his Bachelor of Science degree from Capital Medical University and is currently advancing his clinical expertise through residency while contributing to translational oncology research. His work is focused on prostate cancer, with particular emphasis on identifying therapeutic targets that regulate tumor immunity, a critical area for developing next-generation treatment strategies. Mr. Zhechun Wu has published in reputable international journals, including a recent article in Investigational New Drugs that explored drug targets modulating tumor immune response, a study that has already been cited in related scholarly work, reflecting its scientific significance. His projects are supported by competitive funding from the National Natural Science Foundation of China  and the Beijing Natural Science Foundation, highlighting his ability to secure prestigious grants and deliver research with clinical and academic value. Alongside research, his clinical practice in urology, oncology, and kidney transplantation strengthens his understanding of patient-centered challenges, allowing him to align laboratory findings with real-world medical needs. This dual role as physician and researcher equips him to contribute to both advancing cancer therapeutics and improving clinical outcomes, establishing a foundation for future leadership in medical innovation and academic research.

Profile: ORCID

Featured Publications

Zhang, Y., Qiu, X., Wu, Z., Li, Y., Shen, X., Wu, J., Cao, P., Sun, Z., & Wang, W. (2025). Comprehensive analysis of the association between volatile organic compound pollutants and chronic kidney disease in hypertensive populations: Insights from multi-omics approaches and identification of potential therapeutic targets. Environmental Research, 121966.

Wu, Z., Li, S., Li, Y., Wang, Z., & Wang, W. (2025). Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity. Discover Oncology, 16, 98.

Wu, Z. (2025). Higher sexual frequency correlated with lowered PSA complex levels in U.S. men over 40 and without prostate conditions: A nationwide cross-sectional study. The Journal of Sexual Medicine.